Regulatory and Business Strategy
Joel Ironstone is a medical technology development expert with over 15 years of consulting experience developing novel medical technologies. His experience includes technical development, regulatory approvals and the design and execution of clinical trials.
Presented by Bausch + Lomb
Bausch + Lomb is a subsidiary division of the multinational specialty pharmaceutical company, Valeant Pharmaceuticals International, located in Quebec, Canada. B+L operates within the health care and optics space, with a major focus on marketing, sales and distribution of vision care products.
Looking for the latest funding programs or a valuable partnership? Go beyond combing websites and come to OBIO's “Meet the Non-Dilutive Money!”
Representatives will be Live & In Person from:
- Ontario Centres of Excellence (OCE)
- Ontario Genomics Institute (OGI)
OBIO’s ½ day workshop on health economics, in partnership with and hosted by St. Michael’s Hospital Toronto, will include the following topics:
- The role of payors in healthcare technology adoption in major jurisdictions
- Understanding, designing and executing trials to show product value
- Pricing and market access strategies driven by Health Economics
OBIO® invites you to a unique opportunity to hear Andrew Hutchinson of Alexion Pharmaceuticals, a global pharmaceutical company, provide his valuable insights on best practices for approaching strategic partners in the pharmaceutical industry. Andrew is an External Research & Scouting Lead and is focused on the search, identification and evaluation of business development opportunities for Alexion Pharmaceuticals.
Presented by Kevin Fernandes, M. Eng, P.ENG
CEO, SRED SOLUTIONS
How Big is Your Market Really? Market Segmentation
Presented by Nick Kuryluk of Virtus Insights
Bruce Clarke of B2 Consulting Group will educate participants on:
- Leveraging Market Research
- Case Examples: Validating Value Proposition/Business + Concept/Product
- How to Get Data When You Don’t Have Much Money
- What You Need/Can Do at Each Stage (Ideation, Product Development / Pre-Clinical, Product Launch, Commercial)
OBIO® invites you for the unique opportunity to hear Grant Blevins of FCA Venture Partners, an early stage US venture capital firm, provide his valuable insights on raising capital in the digital health industry via webinar.
OBIO’s H2BB workshop on Market Segmentation will address how to identify different groups of customers and how to use this information to drive your strategy
This workshop will provide an overview of the process illustrated with several relevant examples
OBIO’s H2BB workshop on Primary Market Research will help you understand what primary market research is , what questions it can answer and how it can help you.
Join OBIO's Health Economic Workshop!
This ½ day OBIO workshop hosted by Sunnybrook Medventions will be presented by Edward Black and Dr. Daniel Lace of Reimbursement Strategies
On May 25th, the 2nd Cohort of OBIO's H2BB Program kicked off as over 20 interns coming from as far away as Windsor were onboarded. Interns were provided an overview of health innovation touching on topics which impact the ecosystem including IP, regulatory, manufacturing, and reimbursement. They then were given an overview of various market research tools and the types information that are available from Global Data and Pitchbook, followed by a discussion of how to make their internships a success.
The day concluded with Pitches and Pitchers 2.0 held exclusively for OBIO Pre-CAAP Companies. The 12 Pre-CAAP companies delivered their 2-minute pitch to a packed house that included Investors and other health technology companies!
Please join us for the OBIO 2017 Report Launch and Health Tech Showcase at Queen's Park!
Digital Health Experts Q&A - Grant Blevins and Andrew Bouldin of FCA Venture Partners
BIO is pleased to partner with the National Research Council Canada’s Industrial Research Assistance Program (NRC-IRAP) to present a Partnering Preparation Workshop providing Small and Medium Enterprises (SMEs) in the biotechnology community with in depth insight into partnering with a Multinational Enterprise (MNE).
OBIO Speaker Series
Canada’s Innovation Opportunity in a Trump America
The first presentation in the OBIO 2017 Speaker Series touched on projections and speculations of the Trump Presidency one month in. Talk topics included the; Affordable Care Act, FDA Policy Changes, Immigration & Talent Acquisition and Big Pharma Pricing
- Trump's victory was based on several key factors including; economic dislocation, capturing the suburbs, mastery over new media and the simplicity of his message
- The rhetoric around the Affordable Care Act has started to shift from “repeal and replace” to “repair” Obamacare as a potential compromise position
- The importance of the FDA Commissioner and how the role will steer the future of that agency, stay on the look out for Dr. Scott Gottlieb the favourite candidate among the biosciences lobby in Washington
- When it comes to international students Canada is already punching above our weight in terms of sheer numbers and there will likely be an increased intertest in Canada as a preferred location
- The impact of Trump's comments have a dramatic affect on the stock market when suggesting major changes as seen when he announced the possiblity of a new bidding procedure for biotech and pharma
- Trump's fiscal policies and its impact on Canada will be seen in Trump’s tax plan and how we modify our own policy priorities to respond to the U.S. agenda
Michael Ras - an observer of politics and the intersection of government policy and business - will look at Trump's campaign, the underlying demographic and social shifts that were responsible for his success and will attempt to predict where his policies might take the U.S. Most importantly, he will examine what a Trump administration means to the Canadian economy and in particular our bioscience industry.
Michael Ras - Senior Counsel, HOWE&WYE PR
Michael Ras is a public affairs and strategic communications professional with 20 years of broad experience representing a wide variety of industries at the Federal, Provincial and Local levels of government across Canada. Michael has worked as the Director of Development for the Ivey Centre for Health Innovation and Leadership – a centre dedicated to introducing innovation, higher-levels of leadership and business focus to the Canadian health care system. Michael continues to be engaged on government relations programs for pharmaceutical, biotech and life sciences companies.
“Meet the Non-Dilutive Money!”
OBIO elevated companies beyond combing websites and looking for coins in the cushions, by hosting representatives from OCE, NSERC, NRC-IRAP, OBI and Mitacs who were on hand to answer questions about their respective funding programs.
Some key event highlights:
- Companies learned which programs best suited them based on type and stage and how much each fund delivers
- Companies learned about the latest & current funding programs available
- The organizations ability to partner with each other along the stages of a company’s growth
- Straightforward advice on the various application processes
Navigating HR Dos & Don'ts
OBIO asked and listened! Many of you wanted to know how to navigate the hiring process and in response to that call OBIO delivered the, HR Dos and Don’ts, presented by Joanne Harack, HR Lead, Axela and Owen Roberts, CEO, Nobelex.
Joanne Harack and Owen Roberts have navigated the spectrum of HR challenges in health technology companies and addressed top of mind questions, some of the key takeaways were:
Who to hire first?
- Hiring for the right stage of your company is key
- Avoid the pitfalls of hiring too quickly and too soon
What’s a realistic salary?
- There is a balance, you need to determine what the right salary equity package is to attract and retain employees. This is acheived by identifying what motivates each level of employee and to adjust accordingly.
How to approach virtual management?
- An offsite employee or outsourced consultants still require hands on management